48-week phase 2 study of Sanofi's CD40L antibody frexalimab shows high-efficacy for MS with low relapse rates, leading to global phase 3 studies.
48-week phase 2 study of Sanofi's CD40L antibody, frexalimab, shows promise as a high-efficacy treatment for multiple sclerosis (MS) without lymphocyte depletion. The study demonstrated low annual relapse rates and sustained reduction of disease activity, with frexalimab being generally well-tolerated. Sanofi is initiating global phase 3 studies in relapsing and non-relapsing secondary progressive MS.
April 17, 2024
4 Articles